Novavax Delays U.S. Submission for Covid Vaccine Clearance

Novavax Inc. said it expected to apply for U.S. emergency-use authorization of its Covid vaccine in the fourth quarter, another delay in its bid to gain approval of the closely watched shot.

Novavax filed for emergency clearance of its Covid vaccine in India, Indonesia and the Philippines, according to an emailed statement. A study showed a second dose of the shot resulted in four times more protective antibodies against the virus than the first, the statement said.